CORDIS · 115582 · FP7
EBISC European Bank for induced pluripotent Stem Cells
Coordinator: JANSSEN PHARMACEUTICA NV (BE)
EBiSC is designed to address the increasing demand by iPSC researchers for quality-controlled, disease-relevant research grade iPSC lines, data and cell services. Its goal is to demonstrate an operational banking and distribution service of iPSC lines after 3 years and to establish subsequently for Europe a centralised, not-for-profit bank providing all qualified users with access to scalable, cost-efficient and customised products. The EBiSC Consortium including EFPIA partners boasts the leadership, scientific expertise, facilities, networks and experience to achieve these goals and, being r…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €21.8M toward a total project budget of €34.3M — a funding rate of 64%, with the remainder covered by the consortium partners. The project runs over approximately 4 years from 2014-01-01 to 2017-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from BE
see all →- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · H2020 · €178.2M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · HORIZON · €153.0M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · H2020 · €150.0M
- SGA2 — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101197135 · HORIZON · €120.0M
- SGA3 — COST - Maximising impact861952 · H2020 · €81.8M
- EIT Digital BP — EIT Digital Sustainable Growth101113245 · HORIZON · €33.7M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €21.8M toward a total project budget of €34.3M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by JANSSEN PHARMACEUTICA NV (BE).
- What is the project timeline?
- The project runs from 2014-01-01 to 2017-12-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115582.